OBI Filed an Application of Investigational Device Exemption (IDE) for Phase II Cohort Expansion Human Clinical Trial for Globo H Antibody Drug Conjugate, OBI-999, to FDA

1.Date of occurrence of the event: September 29, 2021 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not applicable 5.Cause of occurrence: OBI filed the application of investigational device exemption (IDE) for “testing immunohistochemistry (IHC) of Globo H expression on tumor cells” to […]

This article is password protected.

To view the content, please enter your password in the field below